A two-component research formulation combining a GHRH-pathway analogue with a growth-hormone secretagogue, allowing investigation of two distinct signalling mechanisms converging on the GH axis. Both components and their quantities should remain explicitly identified.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
CJC No DAC + Ipamorelin is a dual-peptide research formulation combining two synthetic compounds that interact with distinct receptors involved in growth hormone (GH) regulation.
CJC-1295 without DAC, also known as Modified GRF (1-29), is a synthetic analogue of growth hormone-releasing hormone (GHRH). It has been investigated for its ability to stimulate pituitary growth hormone secretion through GHRH receptor activation. Unlike the DAC-containing version, it lacks the albumin-binding modification responsible for prolonged activity.
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue receptor (GHS-R1a) agonist. It interacts with the ghrelin receptor, activating a signaling pathway involved in endogenous growth hormone release.
CJC No DAC + Ipamorelin 5 + 5 mg is presented as an experimental dual-peptide formulation for laboratory and scientific applications. The stated quantities refer to 5 mg of each compound, totaling 10 mg, and should not be interpreted as recommended human dosages.
Product: CJC No DAC + Ipamorelin
Strength: 5 mg + 5 mg (10 mg total)
Alternative names: Modified GRF (1-29) + Ipamorelin
Category: Growth Hormone
Compound classification: Dual synthetic growth hormone secretagogue formulation
Research target: Growth hormone-releasing hormone receptor (GHRHR) and growth hormone secretagogue receptor (GHS-R1a)
Research focus: Growth hormone signaling, pituitary regulation, receptor interactions and GH–IGF-1 axis physiology
Mechanism: Complementary activation of GHRH and ghrelin receptor pathways involved in endogenous growth hormone secretion
Pharmacological profile: Experimental dual-peptide formulation investigated through established receptor pharmacology, with limited direct clinical evidence for the specific combination
Intended use: Laboratory and research use only
A synthetic analogue of growth hormone-releasing hormone (GHRH) studied through the GHRH receptor and downstream GH/IGF-1 axis. Research areas include endocrine signalling, growth-hormone physiology and metabolic regulation.
A synthetic growth hormone secretagogue peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone signalling pathways. Its research landscape includes GH secretion, neuroendocrine regulation and metabolic signalling.
A synthetic growth hormone-releasing peptide investigated for its activity at the ghrelin receptor (GHS-R1a) and its influence on growth-hormone secretory pathways. Its research landscape includes GH release, pituitary signalling and neuroendocrine regulation.
A synthetic fragment derived from the C-terminal region of human growth hormone. Research focuses on the biological properties of this fragment and its relationship to metabolic and GH-associated signalling without representing the complete GH molecule.
A short-acting GHRH-analogue research peptide used to investigate growth-hormone-releasing pathways and GH/IGF-1 signalling. The No-DAC form must be clearly distinguished from albumin-binding CJC-1295 with DAC because their molecular designs are not equivalent.
A growth-hormone secretagogue investigated through ghrelin/GHS receptor signalling and downstream GH physiology. It provides a mechanistically different research route into the GH axis than GHRH analogues such as CJC-1295 and tesamorelin.